These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 38668051)

  • 41. Risk stratifying MDS in the time of precision medicine.
    Cazzola M
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
    Hochman MJ; DeZern AE
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):573-582. PubMed ID: 38594129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TP53 in AML and MDS: The new (old) kid on the block.
    Marks JA; Wang X; Fenu EM; Bagg A; Lai C
    Blood Rev; 2023 Jul; 60():101055. PubMed ID: 36841672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
    Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
    Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myelodysplastic syndromes: moving towards personalized management.
    Hellström-Lindberg E; Tobiasson M; Greenberg P
    Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
    Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
    Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.
    Bănescu C; Tripon F; Muntean C
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
    Malcovati L; Stevenson K; Papaemmanuil E; Neuberg D; Bejar R; Boultwood J; Bowen DT; Campbell PJ; Ebert BL; Fenaux P; Haferlach T; Heuser M; Jansen JH; Komrokji RS; Maciejewski JP; Walter MJ; Fontenay M; Garcia-Manero G; Graubert TA; Karsan A; Meggendorfer M; Pellagatti A; Sallman DA; Savona MR; Sekeres MA; Steensma DP; Tauro S; Thol F; Vyas P; Van de Loosdrecht AA; Haase D; Tüchler H; Greenberg PL; Ogawa S; Hellstrom-Lindberg E; Cazzola M
    Blood; 2020 Jul; 136(2):157-170. PubMed ID: 32347921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cogle CR; Scott BL; Boyd T; Garcia-Manero G
    Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.
    Marques FK; Sabino AP
    Biomed Pharmacother; 2022 Dec; 156():113905. PubMed ID: 36306593
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myelodysplastic syndromes: the pediatric point of view.
    Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
    Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
    Harada H; Harada Y; Kimura A
    Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
    Dan C; Chi J; Wang L
    Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.